Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. TAP
3. DELL
4. ROIV
5. ANET
6. NKE
7. PANW
8. CL
9. SNDK
10. EAT

Go back to Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
(NASDAQ: NRIX) Delayed: 26.14 +0.82 (3.24%)
Previous Close $25.32    52 Week High $ 
Open $25.19    52 Week Low $ 
Day High $26.22    P/E N/A 
Day Low $24.97    EPS $ 
Volume 1,232,152